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Background: Germline DNA mutations that increase the susceptibility of a patient to certain cancers have been
identified in various genes, and patients can be screened for mutations in these genes to assess their level of risk
for developing cancer. Traditional methods using Sanger sequencing focus on small groups of genes and therefore
are unable to screen for numerous genes from several patients simultaneously. The goal of the present study was
to validate a 25-gene panel to assess genetic risk for cancer in 8 different tissues using next generation sequencing
(NGS) techniques.
Methods: Twenty-five genes associated with hereditary cancer syndromes were selected for development of a
panel to screen for risk of these cancers using NGS. In an initial technical assessment, NGS results for BRCA1 and
BRCA2 were compared with Sanger sequencing in 1864 anonymized DNA samples from patients who had
undergone previous clinical testing. Next, the entire gene panel was validated using parallel NGS and Sanger
sequencing in 100 anonymized DNA samples. Large rearrangement analysis was validated using NGS, microarray
comparative genomic hybridization (CGH), and multiplex ligation-dependent probe amplification analyses (MLPA).
Results: NGS identified 15,877 sequence variants, while Sanger sequencing identified 15,878 in the BRCA1 and
BRCA2 comparison study of the same regions. Based on these results, the NGS process was refined prior to the
validation of the full gene panel. In the validation study, NGS and Sanger sequencing were 100% concordant for
the 3,923 collective variants across all genes for an analytical sensitivity of the NGS assay of >99.92% (lower limit of
95% confidence interval). NGS, microarray CGH and MLPA correctly identified all expected positive and negative
large rearrangement results for the 25-gene panel.
Conclusion: This study provides a thorough validation of the 25-gene NGS panel and indicates that this analysis
tool can be used to collect clinically significant information related to risk of developing hereditary cancers.
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Approximately 7% of breast and 11% to 15% of ovarian
cancers are estimated to be due to germline DNA muta-
tions [1-3]. Mutations in the BRCA1 and BRCA2 genes
account for the majority of the mutations that increase
risk for these cancers [1-3]. In addition to these two
genes, mutations in several others, such as MLH1 and
MSH2, can also convey significant increases in risk for
the development of malignancies in other hereditary
cancer syndromes [4]. The detection of germline muta-
tions in blood samples from patients can be extremely
useful for identifying patients at high risk of developing
a malignancy. This genetic information can be used to
guide treatment discussion and genetic counseling for
at-risk family members.
Sanger DNA sequencing has been the standard
method of screening for genetic variants in clinical prac-
tice. In order to use this methodology, users are required
to focus on small groups of genes that are selected based
on a patient’s unique risk factors and family history.
Consequently, the utility of the Sanger method is limited
when analyzing multiple genes from several patients
simultaneously because tests for targeted genes often
need to be conducted serially instead of simultaneously
[5]. However, this upfront selectivity combined with in-
complete follow-through in reflex testing may reduce
the sensitivity of the testing overall.
Next generation sequencing (NGS) platforms provide
an alternative to Sanger DNA sequencing that is more
efficient for the analysis of large gene panels, allowing
for more effective simultaneous screening of multiple
genes [6]. This technique relies on multiplexed sample
preparation followed by massive parallel sequencing and
requires a significant informatics component for analysis
[6]. Because multiple genes can be analyzed at once, de-
lays in the acquisition of genetic data can be reduced [6].
Use of NGS could enable physicians to assess many
genes associated with increased cancer risk at once, pro-
viding results in less time than required for several
Sanger sequencing analyses to be conducted serially.
However, a lack of standardization in sample preparation
techniques, platforms, data analysis methods, variant
classification, and clinical interpretation are significant
challenges to the use of NGS platforms in clinical prac-
tice. To that end, guidelines and recommendations for
NGS have been developed [7,8].
An optimized and validated assay design is critical to
maximizing the analytical sensitivity and specificity of
NGS assays and ensuring high-quality interpretation to
facilitate clinical decision-making. The development
and analytical validation of a clinical NGS panel of 25
genes associated with hereditary cancers that can be
screened simultaneously for maximal efficiency is pre-
sented here.Methods
Development of the 25-gene panel
Twenty-five genes associated with hereditary cancer syn-
dromes [9] were selected for development of a panel to
screen for syndromes associated with 8 primary types of
cancer (breast, ovarian, colon, endometrial, melanoma,
pancreas, gastric, and prostate) using NGS. The genes
included in the panel were: BRCA1, BRCA2 (hereditary
breast and ovarian cancer syndrome); MLH1, MSH2,
MSH6, PMS2, EPCAM – for large rearrangements of
the last two exons only (Lynch syndrome); APC (familial
adenomatous polyposis/attenuated familial adenomatous
polyposis syndrome); MUTYH (MUTYH-associated
colon cancer risk/MUTYH-associated polyposis syn-
drome); CDKN2A (melanoma-pancreatic cancer syn-
drome); PALB2, ATM (hereditary breast and pancreatic
cancer risk); STK11 (Peutz-Jeghers syndrome), PTEN
(PTEN hamartoma tumor syndrome); TP53 (Li-Fraumeni
syndrome); CDH1 (hereditary diffuse gastric cancer syn-
drome); BMPR1A, SMAD4 (juvenile polyposis syndrome);
BARD1 (hereditary breast cancer risk); CHEK2 (hereditary
breast, colorectal and prostate cancer risk); CDK4 (melan-
oma cancer syndrome); NBN (hereditary breast and pros-
tate cancer risk); RAD51C, BRIP1 (hereditary breast and
ovarian cancer risk); and RAD51D (hereditary ovarian
cancer risk) (Table 1). Most of these genes are associated
with medical management guidelines from professional
societies, such as NCCN, but some have currently only
been associated with higher lifetime risks in published
studies and do not have associated medical management
guidelines. Variants were classified using methods con-
sistent with American College of Medical Genetics and
Genomics Guidelines [10].
DNA target preparation and enrichment were per-
formed using the RainDance microdroplet polymerase
chain reaction (PCR) system (RainDance Technologies,
Billerica, Massachusetts). The RainDance microfluidic
system combines microdroplets containing DNA and
PCR reaction mix with microdroplets containing PCR
primer sets. The use of dropletized primer/DNA combi-
nations allowed for use of high numbers of primers in
the library without primer-primer interactions. Custom
primers were then arranged into multiplexes of 5 ampli-
cons for efficient DNA usage and dropletized into the
RainDance library.
A custom primer library to amplify gene regions of
interest was designed using an iterative process. Sequen-
cing regions of coding exons were identified (Table 1)
and flanked by up to 20 bases of upstream and 10 bases
of downstream intronic sequence to allow for variants
that occurred in conserved, proximal splicing elements.
Several extensions to cover potential mutations such as
more distal, putative splicing mutations or other non-
exonic mutations were included in the design [11,12]. A
Table 1 Genes included in the 25-gene NGS panel
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Figure 1 Components of the 25-gene panel. CGH, comparative genomi
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Dance Technologies for automated primer design with
required design criteria, in this case Illumina 2X150
base-pair paired end sequencing, to determine optimal
amplicon length, primer placement and primer tail se-
quences. Putative PCR priming sites were selected by
RainDance Technologies using genome build hg19/
GRCh37 with custom software and compared automat-
ically with public variant databases to avoid nonspecific
priming and common single nucleotide polymorphisms.
Primers which were designed against genes that are cur-
rently tested in this laboratory by Sanger sequencing
were also manually compared against our own variant
lists to avoid common sequence variations that might
interfere with primer binding. The risk of sequence arti-
facts due to interfering variants at primer binding sites is
reduced through amplicon tiling in all but the terminal
primers of gene regions. With an average of >5 ampli-
cons per exon there is enough redundancy for most se-
quence variants that might alter primer bindings in
other amplicons to be detected. This library was then
synthesized and tested for quality and reproducibility.
Shortcomings were addressed through new primer de-
sign before the process was repeated.
This assay can be broadly divided into 3 parts: the se-
quencing portion via NGS; the large rearrangement (LR)
detection via NGS dosage analysis, microarray CGH,
and multiplex ligation-dependent probe amplification
analyses (MLPA); and informatics assisted data review
and reporting, including variant classification (Figure 1).
For the NGS assay, genomic DNA was extracted from
blood samples by QIAsymphony using the DSP DNA
Midi kit (Qiagen, Venlo, The Netherlands), and a fixed
input of 5 μg was fragmented to approximately 3 kb
using sonication (SonicMan, Brooks Life Science Systems,
Spokane, Washington). The reaction mix containing
fragmented DNA and PCR mastermix was dropletized
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system using a RainDance Thunderstorm. The frag-
mented, genomic template for this step is limited so
that amplification is digital for most reactions; roughly
40,000 reaction droplets were inoculated per patient to
ensure that the final PCR products were consistent and
normalized. The resulting emulsion underwent 55 cy-
cles of amplification on a Mastercycler Pro thermocy-
cler (Eppendorf, Hamburg, Germany) after which the
PCR products were bead-purified using AMPure XP
(Beckman Coulter, Brea, California). A 6-nucleotide
“barcode” tag, specific to each sample within a batch,
and Illumina-specific sequencing adaptors were at-
tached using secondary PCR. Purified products were
then pooled and sequenced on the Illumina HiSeq 2500
NGS instrument (Illumina Inc., San Diego, California)
to generate 2X150 base-pair paired end sequencing
reads according to manufacturer instructions. All re-
agents were stored according to and used within the
timeframe specified by manufacturer recommendations.
Portions of the PMS2 and CHEK2 genes have highly
homologous pseudogenes. Therefore, target enrichment
was modified to incorporate long-range PCR to ensure
specificity to the genes of interest. Specific long-range
amplicons (LRAs) were generated by primary PCR per-
formed using LA Taq Hot Start (Takara Bio Inc., Otsu,
Japan) on 50 ng of genomic DNA. LRA products were
diluted 1:10,000, and a second round of PCR was com-
pleted to amplify specific regions of interest and to at-
tach barcode and sequencing adaptors to samples.
Equal amounts of sample were combined and diluted
to 2 nM for sequencing using the Illumina MiSeq NGS
instrument for 2X150 base-pair paired end sequencing
reads. These data for individual patients generated on
the HiSeq and MiSeq are recombined informatically
during data analysis.
NGS informatic data analysis
Base calling was completed using Illumina Sequence
Control Software with Real Time Analysis. Samples had
quality scores assigned, and all sequence reads were
trimmed to remove primers and sequencing bases below
Q30 using an optimized Burrows-Wheeler approach.
The open-source program JAligner (http://jaligner.source
forge.net) was used to align the trimmed sequence
reads to an internal set of reference sequences compris-
ing the genes of this panel and their associated pseudo-
genes. The system automatically discarded all reads
that matched pseudogene reference sequences as well
as or better than the genes of interest.
All data were reviewed using in-house–designed re-
view software. This software annotated allele frequency,
assessed zygosity and performed quality metrics. To as-
sess quality, Q scores and percent mapped reads werecalculated. Using this method, the average depth of
coverage was >1000X, with a minimum depth of cover-
age of 50X per base. By maintaining the average depth
of coverage around 1000X to 2000X the number of bases
with low (50X to 100X) coverage can be minimized. High
depth of coverage becomes important when trying to as-
sess dosage by amplicon quantitation as a method for
detecting large rearrangements. Any region covered by
NGS sequencing with a depth of coverage <50X was re-
peated using Sanger sequencing. After alignment, se-
quence variants were called based on quantitative
thresholds; bases called with a non–wild-type frequency
of <10% are attributed to noise, 30% to 70% are called
heterozygous changes, and 90% to 100% are called
homozygous changes (Figure 2). Bases in intermediate fre-
quencies (10%-30%, or 70%-90%) are followed up by
Sanger sequencing.
Analysis of large rearrangements
Large rearrangements were identified using quantitative
dosage analysis of the data obtained from NGS. This ap-
proach relied on the digital nature of the droplet PCR
process and required the comparison of trimmed,
mapped amplicon read counts for all 96 samples in a
batch. For these data, read counts of each amplicon were
first normalized to the average read count of the sample.
This ratio was then normalized to adjust for variability
across the batch of 96 samples. Next, all of the ampli-
cons that overlapped an exon or region of interest were
combined together into a summary value. Finally, a ratio
for each region of interest was generated for each sample
relative to all others within the batch and plotted as a
scatterplot. This analysis was done using in-house–de-
veloped review software by trained data reviewers
(Figure 3).
Identification of large rearrangements, specifically de-
letions and duplications, was also performed using add-
itional methods to complement NGS. Twenty-three
genes in the panel were assessed using a custom micro-
array comparative genomic hybridization (CGH) chip
(Agilent Technologies, Santa Clara, California). A total
of 349 regions, mainly coding exons along with 100 nu-
cleotides of flanking sequences, were covered by >9,400
custom oligonucleotide probes for an average coverage
of 27 probes per region. Patient genomic DNA was frag-
mented and labeled with Cy5, and reference DNA was
labeled with Cy3 using a custom version of the Agilent
SureTag Labeling Kit. Labeled DNA was then combined
and hybridized to a microarray containing oligonucleo-
tide probes to gene regions. After hybridization, slides
were washed to remove excess hybridization reagents and
non-hybridized DNA. Scanning of washed slides was
completed using an Agilent Microarray Slide Scanner, and
data were extracted using Agilent Feature Extraction
AB
Figure 2 The same variant in NBN as detected by Sanger sequencing (A) and NGS (B). Note that the frequency of alleles at variable
positions, read depth in independent forward and reverse reads and quality scores can be reviewed here. The heterozygous base change
indicated by the arrow in panel A is the same base change selected in the NGS results in panel B. NBN, NBN-associated cancer risk ; NGS, next
generation sequencing.
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oped software using sample dosage normalization, locally
weighted scatterplot smoothing normalization, historic
probe normalization, and custom GC normalization
(Figure 3).
MLPA analysis for large rearrangements in PMS2 and
CHEK2 was conducted using probe mixes P008 and
P190, respectively, from MRC-Holland (Amsterdam,
The Netherlands). Pairs of adjacent oligonucleotide
probes were hybridized to regions of interest, usually
one probe pair in or near each exon. To improve speci-
ficity, probes were designed over gene-specific variants,
to distinguish between homologous pseudogenes and
the actual gene regions of PMS2 and CHEK2. Adjacent
probes were ligated and then amplified by PCR using
fluorescently labeled composite primers that included
genomic target and stuffer sequences to differentiate
products by size. Gene dosage results were analyzed
using GeneMarker software (Softgenetics, State College,
Pennsylvania).Validation procedures
The 25-gene panel was validated using samples submit-
ted for single-syndrome clinical testing to a Clinical
Laboratory Improvement Amendments (CLIA) and
College of American Pathology (CAP) approved labora-
tory. All patients who received clinical testing gave in-
formed consent for testing and were over the age of 18.
Upon completion of clinical testing, all samples were
anonymized for research by Myriad’s Quality Assurance
department. Any samples originating from states with
legislation mandating destruction of biospecimens after
completion of genetic testing were excluded. As a
retrospective study performed on anonymized samples,
this analytical validation was not subject to any add-
itional review (HHS regulation 45 CFR 46). The se-
quencing component of the NGS panel was validated
by comparing NGS with Sanger sequencing results in
100 samples. To facilitate this, Sanger primer sets were
designed and tested for all exons sequenced by the
NGS panel.
Figure 3 (See legend on next page.)
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Figure 3 A contiguous deletion involving EPCAM and MSH2 as seen in both microarray CGH (A) and NGS LR (B) views. In the case of the
microarray CGH plot the data are on a log2 scale with wild-type dosage at 0 on the Y-axis. In the case of the NGS dosage plot, the data are on a
linear scale with wild-type dosage at 2 on the Y-axis. In both cases, a summary overview is available (top) as well as a zoomed in (bottom) view
showing specific probe or amplicon placement. In the summary view, all genes are shown simultaneously with a symbol representing each gene,
and exons proceeding 5’ to 3’ across the X-axis. Note that EPCAM exons 2–3 are also included in the microarray CGH assay for normalization
purposes but are not tested on the NGS LR assay. NGS LR, next generation sequencing large rearrangements.
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gene panel were validated on additional positive samples,
along with the 100 samples used for the sequencing por-
tion of the validation which did not contain large re-
arrangement mutations. Deletion/duplication analyses
on 23 genes were also validated by microarray CGH in
212 anonymized DNA samples and by NGS dosage ana-
lysis on a subset of 110 of these anonymized samples
with sufficient volume. Genomic positive controls were
supplemented with synthetic controls for microarray
CGH. MLPA was validated for PMS2 and CHEK2 in 110
anonymized DNA samples. This set of 110 anonymized
samples is the same set that was used in the microarray
CGH and NGS dosage analysis validations.
Statistical methods
Sensitivity is the proportion of the number of true posi-
tives over the sum of the number of true positives and
false negatives. It is the ability to correctly identify a se-
quence change from the wild type if that change exists.
Specificity is the proportion of the number of true nega-
tives over the sum of the number of true negatives and
false positives. It is the ability to correctly exclude a se-
quence change from the wild type if that change does
not exist.
Lower 95% confidence bounds for sensitivity and spe-
cificity estimates were calculated using Minitab version
15, 1 proportion test, with the Exact method. Note that
Minitab only calculates a 1-sided confidence interval
(CI) when the numerator of the proportion equals the
denominator because the upper bound is 100%. By
reporting the lower limit of the 95% CI, one can claim
with 95% confidence that the actual sensitivity or specifi-
city meets or exceeds the stated sensitivity or specificity.
Results
Initial sensitivity and specificity assessment of BRCA1 and
BRCA2 sequencing
For the initial sequencing assessment, NGS identified
15,877 variants, while prior Sanger sequencing identified
15,878 variants among 1864 anonymized samples from
patients who had previously undergone BRCA1 and
BRCA2 testing. Patients were selected based on personal
history that included cancer, though not limited to
breast or ovarian malignancies. Of these variants, 3.02%
were deleterious or suspected deleterious mutationswhile only 0.67% were variants of uncertain significance.
The results showed an estimated analytical sensitivity for
NGS >99.96% (lower limit of the 95% CI) and an esti-
mated analytical specificity >99.99% (lower limit 95% CI)
for BRCA1 and BRCA2 sequencing. One polymorphism,
BRCA2 c.7806-14C > T, was missed by NGS, determined
to be caused by non-amplification of a PCR allele. The
missed polymorphism was in a DNA sample with a rare
co-occurring 3-base intronic deletion in a PCR primer
binding site (BRCA2 c.7806-64_7806-62del), which has a
frequency of approximately 0.05%. No other differences
in mutations detected were observed, including the 301
indels and 15,577 single-base substitutions identified
here, or sensitivity for different types of mutations be-
tween Sanger sequencing and NGS.
Sensitivity of subsequent NGS data analysis was en-
hanced by using individual amplicon dosage to assess
PCR allele dropout due to rare sequence variants under
primer binding sites. First, the dosage of each amplicon
relative to the rest of the amplicons in the sample is ex-
amined. Next the dosage is compared with the standard
deviation of the amplicon across the whole batch. Based
on these data, any amplicon that appears amplified from
a single allele can be flagged. Flagged regions can be
assessed through follow-up Sanger sequencing. This
improvement was made possible by the enhanced quan-
titative nature of NGS that was not an option with
Sanger sequencing. PCR-based sample preparation for
both NGS and Sanger sequencing shares the same risk
of variants interfering with primer binding but NGS al-
lows for better detectability. Based on these initial posi-
tive results, the 25-gene NGS panel underwent further
validation.
Analytical validation of the 25-gene NGS panel for clinical
testing
At this point changes to the assay were completed and
validation was performed for the sequencing and large
rearrangement components for the entire 25-gene panel
test. NGS and Sanger sequencing were performed in
parallel on 100 anonymized DNA samples. Sequencing
results were 100% concordant for the 3923 collective
variants identified in 100 DNA samples (Table 2). This
included 3884 single base substitutions and 39 indels.
The 39 indels included 4 insertions, 34 deletions, and
one insertion coupled with a deletion. Of these, 20
Table 2 Sanger and next generation sequencing results
Sanger sequencing NGS
Samples 100 100
Amplicons (per sample) 370 1969
Bases analyzed (per sample) 88,631 88,631
Total positive bases 3923 3923
•Single base substitutions 3884 3884
•Small indels 39 39
Total negative bases 8,859,177 8,859,177
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gions flanking the exons that are involved in splicing.
Analytical sensitivity of the NGS assay was estimated to
be >99.92% (lower limit of 95% CI). Analytical specificity
of the NGS assay was estimated to be >99.99% (lower
limit of 95% CI). Reproducibility studies were also per-
formed, wherein 4 DNA samples were run in triplicate
per batch, across 3 different batches. The data showed
100% concordant calls, which demonstrated intra-batch
and inter-batch reproducibility.
The large rearrangement component of the assay was
validated using an additional set of 212 anonymized DNA
samples with known large rearrangement genotypes. Dele-
tion/duplication analysis on 23 of the 25 genes in the
panel was performed by microarray CGH, which correctly
identified all 51 genomic positive controls, including repli-
cates and reproducibility controls, across different genes
among the 212 anonymized DNA samples (Table 3). A
partial set of 110 of these samples with sufficient volume,
including 49 of the positive samples, was also processed
using NGS for large rearrangement dosage analysis. Of
the 49 large rearrangement positive samples processed, 48
produced results which were all concordant with the
expected sample large rearrangements. The sample con-
taining the final LR, a MSH2 deletion of exons 1–6, did
not successfully complete laboratory processing and did
not undergo data analysis. For some genes where rare gen-
omic positive controls were not available, we supple-
mented the validation studies with synthetic positive
controls created with restriction enzyme digests of gen-
omic DNA for microarray CGH analysis. The results
were consistent with simulated deletions in the affected
regions. In addition, deletion/duplication analysis for
the pseudogene-containing PMS2 and CHEK2 genes
was validated using MLPA on 110 anonymized DNA
samples with known genotypes. MLPA correctly identi-
fied all 5 genomic positive controls in PMS2 and
CHEK2 among these 110 anonymized DNA samples.
Discussion
Recent advances in NGS and sample enrichment tech-
nologies allow for simultaneous assessment of multiplegenes. Hereditary cancer panels have been constructed
incorporating genes underlying well characterized cancer
syndromes, such as BRCA1 and BRCA2, along with
more recently discovered genes associated with in-
creased cancer risk [13]. The use of gene panels in her-
editary cancer risk assessment is increasing and studies
to assess the prevalence of mutations among patients
commonly referred for genetic testing have recently been
published [9,14,15]. Additional studies are underway to
more fully define the benefits and limitations of panel
testing in the clinical setting. Analytical validation is a
critical step in the laboratory development process to fa-
cilitate the availability of highly robust and reproducible
clinical tests. The current study demonstrates the analyt-
ical validation of a 25-gene hereditary cancer panel by
comparing results of Sanger sequencing and other
methods to results of the NGS assay.
Initial analysis of BRCA1 and BRCA2 gene variants
facilitated the optimization of this NGS assay that
allowed for validation of a comprehensive 25-gene
panel. Process improvements in NGS data analysis
based on these initial results were able to enhance the
sensitivity of the assay for detection of low coverage re-
gions that were suggestive of potential deletions or PCR
allele dropouts. This initial analysis also supported the
standardized NGS methodology so that it could then be
applied to the collection of mutation data that could be
clinically significant using the 25-gene panel. This is
important because NGS is being used clinically, but
there continue to be challenges in standardizing the dif-
ferent components that include the analytical wet
bench process (sample preparation, target enrichment,
NGS sequencing) and the bioinformatics pipeline for
NGS [7]. Therefore, it is important for each lab to dem-
onstrate a robust validation of their clinical NGS
assays.
The validation of the gene panel presented here offers
the opportunity to test a system that incorporates la-
boratory information management system tracking for
all steps through the lab and custom software to support
timely and accurate analysis of clinical data. Further-
more, it allowed testing and validation of a system for
handling large numbers of novel variants requiring re-
view and classification, and a comprehensive reporting
system to meet the needs of patients and their health
care providers.
The validation study showed that the 25-gene panel
meets the rigorous quality standards necessary to pro-
vide useful data in the clinical setting. The results of the
25-gene panel were shown to be equivalent to those ob-
tained using Sanger DNA sequencing analysis. Extensive
validation covered the sequencing and large rearrange-
ment components of the assay with suitably large study
sets to provide reliable data.
Table 3 Previously characterized large rearrangements that were included in the study
Gene Mutation microarray CGH NGS dosage analysis MLPA
APC deletion promoter 1B - exon 3 detected detected n/a
deletion exon 4 detected detected n/a
BRCA1 duplication promoter 1A - exon 2 detected detected n/a
deletion promoter 1A - exon 19 detected detected n/a
duplication exons 5 - 7 detected detected n/a
deletion exon 13 detected n/a – insufficient volume n/a
duplication exon 13 detected detected n/a
deletion exons 15 – 16 detected n/a – insufficient volume n/a
deletion exons 16 - 17 detected detected n/a
deletion exon 24 detected detected n/a
BRCA2 duplication exons 12 - 13 detected detected n/a
EPCAM deletion exons 2 - 3' UTR detected detected n/a
MLH1 deletion exons 4 - 9 detected detected n/a
deletion exon 13 detected detected n/a
deletion exon 14 detected detected n/a
deletion exon 16 detected detected n/a
MSH2 deletion exon 1 detected detected n/a
deletion exons 1 - 6 detected No Result n/a
duplication exons 1 - 6 detected detected n/a
deletion exons 1 - 7 detected detected n/a
deletion exons 1 - 8 detected detected n/a
deletion exons 1 - 10 detected detected n/a
deletion exons 8 - 15 detected detected n/a
deletion exon 16 detected detected n/a
MSH6 deletion exons 4 (3' end) - 10 detected detected n/a
MUTYH duplication exon 1 detected detected n/a
PMS2 deletion exon 10 n/a n/a detected
deletion exons 1 - 5 n/a n/a detected
deletion exons 13 - 14 n/a n/a detected
deletion exons 14 - 15 n/a n/a detected
deletion exons 9 - 11 n/a n/a detected
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leveraging multiple orthogonal methods during the val-
idation. For example, sequencing variations were con-
firmed with Sanger sequencing (Figure 2) and NGS
dosage analysis results were confirmed by microarray
CGH (Figure 3). Though improvements in this process
may still be made, the NGS system for detection of large
rearrangement yielded 100% concordant results for all
the large rearrangements in regions covered by both the
RainDance and microarray CGH assays. Furthermore,
the ability to assess dosage of amplicons allows users to
catch some cases of allelic dropout that could be caused
by sequence variants under terminal primers which
would not be observable in overlapping amplicons.There are numerous potential advantages to LR detec-
tion via NGS. In addition to lowering the amount of
DNA required for multiple assays and, therefore, requir-
ing fewer redraws for patients, it also allows for very
specific amplicon placement. This is important when
dealing with pseudogenes, which are present in many of
the genes in this panel, and means that dosage data from
the actual coding bases of interest is retrieved rather
than relying on nearby, and often intronic, divergent se-
quences. Finally, the PCR-based nature of the enrich-
ment could also allow for the detection of Alu insertions
that disrupt the PCR amplicons used for enrichment,
and cause them to either fail to amplify or to amplify
poorly. This is important as Alu insertions have been
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occur as founder mutations such as the Alu insertion
BRCA2 exon 3 (c.156_157insAlu) in Portuguese popula-
tions [16]. These mutations are generally not detected
by methods such as microarray CGH and MLPA. In
addition, large rearrangements in PMS2 and CHEK2
were also assessed using MLPA, and non-pseudogene
portions were confirmed against NGS and microarray
CGH. This concordance between orthogonal methods
confirms the strength of this testing platform.
There are some limitations to the study presented
here. First, the validation was limited to blood-derived
samples. This restricted, at least initially, the availability
of the test to one sample type. In addition, rare variants
such as deep intronic sequence changes, and rare large
rearrangements such as genomic inversions, may not be
identified using the PCR-based target enrichment ap-
proach used in this assay.
Use of this gene panel can help define a patient’s can-
cer risk and define management options, including
changes in routine surveillance procedures at a cost that
is comparable to that of single gene testing [17,18]. Im-
portantly, the genes in the panel were selected because
they could provide clinically significant data, not just an
assessment of risk. The availability of a robust assay for
these genetic risk factors that uses a standardized ana-
lysis procedure such as the one presented here can facili-
tate more widespread screening for hereditary cancer
syndromes.
Conclusions
These findings represent a thorough validation of the
25-gene hereditary pan-cancer panel. The results dem-
onstrate that the NGS panel can be used to screen pa-
tients for mutations associated with hereditary cancers
in a variety of different tissues with a sensitivity and spe-
cificity comparable to that of Sanger sequencing. The
NGS panel has the advantage of being able to simultan-
eously screen for multiple genes from several different
patients at the same time. Widespread use of this stan-
dardized genetic risk assessment tool could increase the
identification of patients at high risk for these cancers
and potentially improve care by changing surveillance
procedures and/or treatment of malignancies.
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